A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities

Journal of Clinical Psychiatry

Volumn 64, Issue 6, 2003, Pages 726-730

  Fontaine, Catherine S ^a   Hynan, Linda S ^a   Koch, Kathleen ^a   Martin Cook, Kristin ^a   Svetlik, Doris ^a   Weiner, Myron F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAL HYDRATE; LORAZEPAM; OLANZAPINE; RISPERIDONE;

AGED; ARTICLE; ASYSTOLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DIAPHORESIS; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FALLING; FEMALE; FEVER; HUMAN; HYPERTENSION; LEUKOCYTOSIS; LONG TERM CARE; MALE; NEUROPSYCHIATRY; NURSING HOME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SCORING SYSTEM; SYNCOPE; TREATMENT OUTCOME;

EID: 0038209814     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0617     Document Type: Article

References (14)

1. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999;60:107-115
2. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000;57:968-976
3. Tariot PN, Salzman C, Yeung PP, et al. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 2000;22:1068-1084
4. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
5. Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in Alzheimer's disease patients: a randomized placebo-controlled clinical trial. Neurology 2000;55:1271-1278
6. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314
7. Auer SR, Monteiro IM, Reisberg B. The Empirical Behavioral Pathology in Alzheimer's Disease (E-BEHAVE-AD) Rating Scale. Int Psychogeriatr 1996;8:247-266
8. Wilkinson IM, Graham-White J. Psychogeriatric Dependency Rating Scales (PGDRS): a method of assessment by nurses. Br J Psychiatry 1980;137:558-565
9. Helmes E, Csapo KG, Short JA. Standardization and validation of the Multidimensional Observational Scale for Elderly Subjects (MOSES). J Gerontol 1987;42:395-405
10. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
11. Weiner MF, Martin-Cook K, Svetlik DA, et al. The Quality of Life in Late-Stage Dementia Scale (QUALID). J Am Med Dir Assn 2000;1: 114-116
12. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:534-537
13. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
14. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19